The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers
Cells,
Journal Year:
2025,
Volume and Issue:
14(5), P. 382 - 382
Published: March 5, 2025
The
peremptory
need
to
circumvent
challenges
associated
with
poorly
differentiated
epithelial
endometrial
cancers
(PDEECs),
also
known
as
Type
II
(ECs),
has
prompted
therapeutic
interrogation
of
the
prototypically
intractable
and
most
prevalent
gynecological
malignancy.
PDEECs
account
for
cancer-related
mortalities
due
their
aggressive
nature,
late-stage
detection,
poor
response
standard
therapies.
are
characterized
by
heterogeneous
histopathological
features
distinct
molecular
profiles,
they
pose
significant
clinical
propensity
rapid
progression.
Regardless
complexities
around
PDEECs,
still
being
administered
inefficiently
in
same
manner
clinically
indolent
readily
curable
type-I
ECs.
Currently,
there
no
targeted
therapies
treatment
PDEECs.
realization
new
options
transformed
our
understanding
enabling
more
precise
classification
based
on
genomic
profiling.
transition
from
a
provided
critical
insights
into
underlying
genetic
epigenetic
alterations
these
malignancies.
This
review
explores
landscape
focus
identifying
key
subtypes
mutations
that
variants.
Here,
we
discuss
how
correlates
outcomes
can
refine
diagnostic
accuracy,
predict
patient
prognosis,
inform
strategies.
Deciphering
underpinnings
led
advances
precision
oncology
protracted
remissions
patients
untamable
Language: Английский
Liquid‒liquid phase separation and poly(ADP‒ribosyl)ation in the context of ultraviolet radiation-induced stress in mammalian cells
Biophysical Reviews,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 11, 2025
Language: Английский
Enhancing Radiation Therapy with PARP Inhibition in Soft Tissue Sarcomas: A Promising Synergy Requiring Specific Attention to Normal Tissues?
Annals of Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Language: Английский
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design
Journal of Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
68(1), P. 18 - 48
Published: Dec. 26, 2024
PARP
(poly-ADP
ribose
polymerase)
has
received
widespread
attention
in
cancer
treatment.
Research
shown
that
plays
a
crucial
role
DNA
damage
repair
and
become
popular
target
for
drug
design.
Based
on
the
mechanism
of
"synthetic
lethality",
multiple
PARPis
(PARP
inhibitors)
have
been
launched
treatment
BRCA
deficient
tumors.
For
example,
approved
significant
potential
treatment,
particularly
breast
cancers
associated
with
BRCA1/BRCA2
deficiencies.
However,
clinical
efficacy
safety
inhibitors
different
remain
issues
cannot
be
overlooked.
The
design
aims
to
eliminate
their
resistance
broaden
application
scope.
Designing
selective
PARP-1
is
also
strategy.
PROTACs
(Proteolysis
Targeting
Chimeras)
degrade
novel
Language: Английский